- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | Zhaoke Ophthalmology Expects Multiple Product Approvals in 2HYY; Aims to Expand International Network to Latin America or South America This Year | 3 | AASTOCKS | ||
| 25.03. | ZHAOKE OPHTH-B (06622): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 11.03. | ZHAOKE OPHTH-B (06622): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 29.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ZHAOKE OPHTHALMOLOGY'S PARTNER TENPOINT THERAPEUTICS, LTD. RECEIVES FDA APPROVAL FOR BRIMOCHOL PF IN ... | - | HKEx | ||
| 26.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ADVANCING COMMERCIALIZATION OF BRIMOCHOL PF FOR PRESBYOPIA IN SINGAPORE AND VIETNAM THROUGH PARTNERSHIPS ... | 1 | HKEx | ||
| 13.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - REGISTRATION APPLICATION FOR ATROPINE SULFATE EYE DROPS ACCEPTED FOR EVALUATION BY AUSTRALI'S THERAPEUTIC ... | 1 | HKEx | ||
| ZHAOKE OPHTHALMOLOGY Aktie jetzt für 0€ handeln | |||||
| 08.12.25 | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO STRATEGIC PARTNERSHIP WITH TSH BIOPHARM TO COMMERCIALIZE BRIMOCHOL PF IN TAIWAN REGION | 1 | HKEx | ||
| 24.11.25 | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF PAN-90806 APPROVED BY NMPA AND MARKETING AUTHORIZATION FOR EPINASTINE ... | 2 | HKEx | ||
| 06.11.25 | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO DISTRIBUTION AGREEMENT WITH PT FERRON TO COMMERCIALIZE BRIMOCHOL PF IN INDONESIA | - | HKEx |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIONTECH | 81,40 | -0,06 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| SUMMIT THERAPEUTICS | 19,670 | +1,86 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| CG ONCOLOGY | 67,69 | -1,25 % | H.C. Wainwright hebt Kursziel für CG Oncology auf 100 US-Dollar an |
ZHAOKE OPHTHALMOLOGY LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,306 Euro und damit +0,66 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZHAOKE OPHTHALMOLOGY LTD finden Sie auf Wallstreet Online.